Evaxion to Present New Preclinical Data for AML Vaccine EVX-04 at EHA 2026, Plans H2 2026 CTA
EVAX has more than doubled off its 52-week low of $1.48.
Summary
Evaxion announced it will present new preclinical data for its off-the-shelf AML vaccine candidate, EVX-04, at the EHA 2026 Congress and plans to submit a Clinical Trial Application in the second half of 2026.
Key Events · Product Development and Regulatory · EVAX
-
Preclinical Data Presentation for EVX-04
Evaxion will present new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the European Hematology Association (EHA) 2026 Congress on June 13, 2026.
-
Clinical Trial Application Planned
The company plans to submit a Clinical Trial Application (CTA) for EVX-04 in the second half of 2026, marking a step towards clinical testing.
-
AI-Immunology™ Platform Validation
EVX-04 was developed using Evaxion's proprietary AI-Immunology™ platform, targeting non-conventional endogenous retrovirus (ERV) tumor antigens, demonstrating the platform's capability in identifying novel cancer targets.
Analysis · EVAX · Life Sciences
Evaxion is advancing its pipeline with new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia. The presentation at a major hematology congress and the stated plan to submit a Clinical Trial Application (CTA) in the second half of 2026 indicate progress towards clinical development for this candidate, which is significant for a clinical-stage biotech company.
At the time of this filing, EVAX was trading at $4.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $35.2M. The 52-week trading range was $1.48 to $12.15. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.